Safety
appetite loss, anemia
ADVERSE EVENTS, APPETITE LOSS, ADVERSE EVENT, ANEMIA
Overall, adverse events were manageable, without new concerns of safety in comparison to the known safety profiles for neoadjuvant nivolumab monotherapy and nivolumab plus chemotherapy. Of the 52 patients in the safety-evaluable population, 36 (69.2%) experienced at least one immune-related adverse event during neoadjuvant treatment, and 13 (25.0%) experienced grade ≥ 3 adverse events. Exhaustion (40.3%), appetite loss (32.7%), and anemia (28.8%) were among the most common grade 1/grade 2 immune-related adverse events. White blood cell count reduction (16.7%, 